Callitas Theraputics Inc., a wholly owned subsidiary of Callitas Health Inc.

M Pharmaceutical Reforecasts 2017 and 2018 Revenues Upward

< BACK

CINCINNATI, OH, USA (July 7, 2017) – M Pharmaceutical Inc. (CSE: MQ, OTCQB: MPHMF, FWB: T3F2), (the “Company” or “M Pharma”), a clinical-stage company developing innovative technologies for weight management and female health and wellness, today announced that it has re-forecasted it’s 2017 third & fourth quarter revenues to reflect increases in current order volume and expected new product launches from longtime distribution partners, branded product launches in the US and Canada, and sales to new distribution/marketing partners in foreign markets.  These 2017 revenue numbers will also dramatically increase the company’s revenue projections for 2018 and beyond.

“Our strategy all along was to maximize the assets that we acquired from 40J’s LLC earlier this year,” said Gary Thompson President & CEO of M Pharmaceutical.  “Our plan called for expanding existing contracts, penetrating new markets and commercializing products previously sitting in the 40J’s pipeline. We are off to an excellent start and with the right amount of focus we should exceed all expectations for revenue growth in the next 18 months, “ add Mr. Thompson.

Current Sales Partners: M-Pharma was recently informed that the one of its customers has received new product approvals in new foreign markets, both in the Americas and in Asia, and will be launching operations in those markets in Q3 & Q4, 2017.  In addition to the expansion into new markets, M Pharma is in late stage discussions with some current business partners for the sale of newly developed topical formulations of its menthol and L-arginine technology, in multiple topical formats for a variety of treatment conditions.  Lastly, M Pharma will be renewing its push to be more integrated with the current distribution partners in their marketing and sales initiatives; road shows, sales meetings, distributor events, and other means to help drive sales of M Pharma technologies.

Branded Product Launches: M-Pharma has plans to launch multiple new, branded products in numerous sales channels in the US and Canadian markets in Q’s 3 & 4, 2017, with additional product line launches in 2018 to advance top-line revenues and profitability.  These multiple pipeline products were acquired from 40J’s LLC earlier this year and represent only a sample of the technologies currently working their way to commercialization.

New Sales Partners in Foreign Markets: M Pharma has developed a commercial business development strategy to advance product sales in foreign markets, and has begun executing on this plan.  M Pharma has and will be executing CDAs with local firms in the EEC, Mexico, Brazil and Australia.  We have begun commercial discussions with multiple partners in these foreign markets, with product proposals and sales, distribution, and licensing contracts being discussed.

About M Pharmaceutical

Formed in early 2015, M Pharmaceutical Inc. is a clinical-stage company developing innovative technologies for obesity, weight management and Female Health & Wellness.  In addition to its recent acquisitions of C-103, a reformulation of Orlistat and assets from 40J’s LLC, the Company is scheduled to launch their FDA cleared fertility product branded as ToConceive sometime in the third quarter of 2017.

M Pharmaceutical Inc. trades on the Canadian Securities Exchange (CSE) under the ticker symbol “MQ” as well as on the OTCQB as “MPHMF” and FWB (Frankfurt Stock Exchange) as “T3F2.”

For more information contact:
M Pharma Investor Relations
Phone: +1 (859) 868-3131
www.mpharma.ca

Notice regarding Forward Looking Statements: This news release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the regulatory approval, commercialization of the rights to the Company’s biomedical & drug technologies, and acquisition of new products.  Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com and the Company’s filings to the CSE at www.cnsx.ca.  Such risk factors may cause the inability of the Company to successfully commercialize any of its biomedical technologies.

Notice regarding investigational devices: C-103  and Extrinsa are investigational drugs or devices and are not currently available outside of approved clinical trials.  Claims regarding the safety and efficacy of these devices have not been evaluated by Health Canada, the U.S. Food and Drug Administration, or any other international regulatory body.

ABOUT CALLITAS

As a company, our number one goal is helping people by bringing products to market that improve quality of life. All our drug treatments and biomedical technologies fit our mission to deliver breakthrough products and services that reduce invasiveness and enhance daily living.

INVESTOR INQUIRIES

  • 1.859.868.3131
  • investors@callitas.com

  • 187 Pavilion Parkway
    Suite 200
    Newport, Kentucky 41071

PRESS AND MEDIA INQUIRIES

  • pressroom@callitas.com

PRODUCT INQUIRIES

2017-07-31T07:52:57+00:00